Sarepta Therapeutics, Inc. (SRPT)

Mixed fundamentals: historical revenue growth is strong, but profitability swung sharply negative in FY2025 and the latest filings describe ELEVIDYS-related safety/label changes pressuring near-term revenue. Liquidity remains solid (cash/investments near $0.9B plus an undrawn revolver), which reduces near-term solvency risk, but regulatory and execution risk stays high—best treated as a watchlist idea until the revenue trajectory and FDA pathway are clearer.

Near-term tape is a two-sided ELEVIDYS story: a regulator-confirmed Federal Circuit revival of the Regenxbio patent suit (2026-08-26) and a five-month ENHANCE safety-study slip (2026-08-27) sit against a rumored +13% best-week-in-five-months rally on late-2026 data anticipation with 31% short interest. Sentiment delta is indeterminate on a sparse 30–90d baseline, and moderate red-flag caps apply (confirmed material litigation; conflicting signals).

Mixed 3/5: the intermediate uptrend is intact — price 20.11 sits above SMA50 (18.55) and SMA200 (19.27), and ADX14 28.63 confirms real trend strength — but the short-term tape is corrective: price is below SMA20 (20.75), EMA9 (20.62) and EMA21 (20.34), and MACD line (0.52) is above zero yet below its signal (0.81) with a slightly widening negative histogram (-0.28). Williams %R -85.40 is deeply oversold as price tests the 19.62-19.75 support zone (09-16 low 19.72 / 09-18 low 19.62) after a ~15% retrace from the 09-09 high 23.22. RSI14 50.23 is neutral, and the 09-18 decline (-2.5%) came on heavy volume (6.29M shares, the highest since 09-08), which tempers the read to a dip-buy at support rather than a momentum confirmation. That is a score-3 setup: bullish structure, not-yet-turned short-term momentum.